These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9737384)

  • 21. [M-29 human diploid cells line--a substrate for the production of antiviral vaccines].
    Borisova TK; Zverev VV; Mironova LL; Koniushko OI; Zabiiaka IuI; Shukhmina NR; Vashchenko VI
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (3):43-8. PubMed ID: 21809644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination vaccines.
    Chokephaibulkit K
    J Med Assoc Thai; 2002 Aug; 85 Suppl 2():S694-9. PubMed ID: 12403249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral oncogenicity and viral vaccines--general comments.
    Gerber P
    Natl Cancer Inst Monogr; 1968 Dec; 29():447-8. PubMed ID: 4888932
    [No Abstract]   [Full Text] [Related]  

  • 24. New viral vaccines.
    Arvin AM; Greenberg HB
    Virology; 2006 Jan; 344(1):240-9. PubMed ID: 16364754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of the Oka vaccine strain of varicella-zoster virus.
    Yamanishi K
    J Infect Dis; 2008 Mar; 197 Suppl 2():S45-8. PubMed ID: 18419407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
    Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
    Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downstream processing of viral vectors and vaccines.
    Morenweiser R
    Gene Ther; 2005 Oct; 12 Suppl 1():S103-10. PubMed ID: 16231042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. History of the acceptance of human diploid cell strains as substrates for human virus vaccine manufacture.
    Hayflick L; Plotkin S; Stevenson RE
    Dev Biol Stand; 1987; 68():9-17. PubMed ID: 3691964
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines.
    Chen P; Zhang KH; Na T; Wang L; Yin WD; Yuan BZ; Wang JZ
    Sci Rep; 2017 Oct; 7(1):12484. PubMed ID: 28970485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reappraisal of karyological monitoring of diploid cell substrates.
    Moorhead PS
    Dev Biol Stand; 1976 Dec 13-15; 37():157-61. PubMed ID: 1031682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell substrates for human virus vaccine preparation--general comments.
    Hayflick L
    Natl Cancer Inst Monogr; 1968 Dec; 29():83-91. PubMed ID: 5720814
    [No Abstract]   [Full Text] [Related]  

  • 36. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative detection of RT activity by PERT assay: feasibility and limits to a standardized screening assay for human vaccines.
    André M; Morgeaux S; Fuchs F
    Biologicals; 2000 Jun; 28(2):67-80. PubMed ID: 10885614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoplastic properties of animal cell lines. Methods for determining neoplastic properties.
    Foley GE
    Natl Cancer Inst Monogr; 1968 Dec; 29():217-28. PubMed ID: 4888929
    [No Abstract]   [Full Text] [Related]  

  • 39. Neoplastic properties of animal cell lines. Methods for determining neoplastic properties--discussion.
    Dawe CJ
    Natl Cancer Inst Monogr; 1968 Dec; 29():229-32. PubMed ID: 5720795
    [No Abstract]   [Full Text] [Related]  

  • 40. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
    Furesz J
    Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.